Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks against Plasmodium spp. infection in Myanmar: A stepped-wedge cluster randomised trial.

Abstract

BACKGROUND:

The World Health Organization has yet to endorse deployment of topical repellents for malaria prevention as part of public health campaigns. We aimed to quantify the effectiveness of repellent distributed by the village health volunteer (VHV) network in the Greater Mekong Subregion (GMS) in reducing malaria in order to advance regional malaria elimination.

METHODS AND FINDINGS:

Between April 2015 and June 2016, a 15-month stepped-wedge cluster randomised trial was conducted in 116 villages in Myanmar (stepped monthly in blocks) to test the effectiveness of 12% N,N-diethylbenzamide w/w cream distributed by VHVs, on Plasmodium spp. infection. The median age of participants was 18 years, approximately half were female, and the majority were either village residents (46%) or forest dwellers (40%). No adverse events were reported during the study. Generalised linear mixed modelling estimated the effect of repellent on infection detected by rapid diagnostic test (RDT) (primary outcome) and polymerase chain reaction (PCR) (secondary outcome). Overall Plasmodium infection detected by RDT was low (0.16%; 50/32,194), but infection detected by PCR was higher (3%; 419/13,157). There was no significant protection against RDT-detectable infection (adjusted odds ratio [AOR] = 0.25, 95% CI 0.004-15.2, p = 0.512). In Plasmodium-species-specific analyses, repellent protected against PCR-detectable P. falciparum (adjusted relative risk ratio [ARRR] = 0.67, 95% CI 0.47-0.95, p = 0.026), but not P. vivax infection (ARRR = 1.41, 95% CI 0.80-2.47, p = 0.233). Repellent effects were similar when delayed effects were modelled, across risk groups, and regardless of village-level and temporal heterogeneity in malaria prevalence. The incremental cost-effectiveness ratio was US$256 per PCR-detectable infection averted. Study limitations were a lower than expected Plasmodium spp. infection rate and potential geographic dilution of the intervention.

CONCLUSIONS:

In this study, we observed apparent protection against new infections associated with the large-scale distribution of repellent by VHVs. Incorporation of repellent into national strategies, particularly in areas where bed nets are less effective, may contribute to the interruption of malaria transmission. Further studies are warranted across different transmission settings and populations, from the GMS and beyond, to inform WHO public health policy on the deployment of topical repellents for malaria prevention.

TRIAL REGISTRATION:

Australian and New Zealand Clinical Trials Registry (ACTRN12616001434482).

• Authors: Paul A Agius, Julia C Cutts, Win Han Oo, Aung Thi, Katherine O'Flaherty, Kyaw Zayar Aung, Htin Kyaw Thu, Poe Poe Aung, Myat Mon Thein, Nyi Nyi Zaw, Wai Yan Min Htay, Aung Paing Soe, Zahra Razook, Alyssa E Barry, Win Htike, Angela Devine, Julie A Simpson, Brendan S Crabb, James G Beeson, Naanki Pasricha, Freya J I Fowkes
• Journal: PLoS medicine (PLoS Med) Vol. 17 Issue 8 Pg. e1003177 (08 2020) ISSN: 1549-1676 [Electronic] United States
• PMID: 32817632 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Insect Repellents

Topics

• Administration, Topical
• Adolescent
• Adult
• Child
• Cluster Analysis
• Community Health Services (economics, methods)
• Cost-Benefit Analysis (methods)
• Female
• Humans
• Insect Repellents (administration & dosage, economics)
• Malaria, Falciparum (economics, epidemiology, prevention & control)
• Malaria, Vivax (economics, epidemiology, prevention & control)
• Male
• Myanmar (epidemiology)
• Pregnancy
• Treatment Outcome
• Volunteers
• Young Adult